Literature DB >> 23716595

STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.

Sarah R Walker1, Erik A Nelson, Jennifer E Yeh, Luca Pinello, Guo-Cheng Yuan, David A Frank.   

Abstract

Inappropriate activation of the transcription factors STAT3 and STAT5 has been shown to drive cancer pathogenesis through dysregulation of genes involved in cell survival, growth, and differentiation. Although STAT3 and STAT5 are structurally related, they can have opposite effects on key genes, including BCL6. BCL6, a transcriptional repressor, has been shown to be oncogenic in diffuse large B cell lymphoma. BCL6 also plays an important role in breast cancer pathogenesis, a disease in which STAT3 and STAT5 can be activated individually or concomitantly. To determine the mechanism by which these oncogenic transcription factors regulate BCL6 transcription, we analyzed their effects at the levels of chromatin and gene expression. We found that STAT3 increases expression of BCL6 and enhances recruitment of RNA polymerase II phosphorylated at a site associated with transcriptional initiation. STAT5, in contrast, represses BCL6 expression below basal levels and decreases the association of RNA polymerase II at the gene. Furthermore, the repression mediated by STAT5 is dominant over STAT3-mediated induction. STAT5 exerts this effect by displacing STAT3 from one of the two regulatory regions to which it binds. These findings may underlie the divergent biology of breast cancers containing activated STAT3 alone or in conjunction with activated STAT5.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23716595      PMCID: PMC3719667          DOI: 10.1128/MCB.01620-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

Review 1.  StAT signaling in cancer: insights into pathogenesis and treatment strategies.

Authors:  David A Frank
Journal:  Cancer Treat Res       Date:  2003

2.  Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas.

Authors:  Xing Wang; Zhiping Li; Akira Naganuma; B Hilda Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

3.  Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.

Authors:  M Bar-Natan; E A Nelson; S R Walker; Y Kuang; R J Distel; D A Frank
Journal:  Leukemia       Date:  2011-12-02       Impact factor: 11.528

4.  FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.

Authors:  Silvia Fernández de Mattos; Abdelkader Essafi; Inês Soeiro; Alexandra M Pietersen; Kim U Birkenkamp; Corinne S Edwards; Anthony Martino; Brad H Nelson; Julia M Francis; Marius C Jones; Jan J Brosens; Paul J Coffer; Eric W-F Lam
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

5.  BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation.

Authors:  Suresh Logarajah; Patricia Hunter; Matthew Kraman; Dawn Steele; Sunil Lakhani; Lynda Bobrow; Ashok Venkitaraman; Simon Wagner
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

6.  Induction of relaxin messenger RNA expression in response to prolactin receptor activation requires protein kinase C delta signaling.

Authors:  C A Peters; E T Maizels; M C Robertson; R P Shiu; M S Soloff; M Hunzicker-Dunn
Journal:  Mol Endocrinol       Date:  2000-04

Review 7.  STAT signaling in the pathogenesis and treatment of leukemias.

Authors:  T S Lin; S Mahajan; D A Frank
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

8.  Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice.

Authors:  Elena Iavnilovitch; Robert D Cardiff; Bernd Groner; Itamar Barash
Journal:  Int J Cancer       Date:  2004-11-20       Impact factor: 7.396

9.  Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha).

Authors:  Reinhard Bos; Paul J van Diest; Petra van der Groep; Astrid E Greijer; Mario A J A Hermsen; Ingrid Heijnen; Gerrit A Meijer; Jan P A Baak; Herbert M Pinedo; Elsken van der Wall; Avi Shvarts
Journal:  Oncogene       Date:  2003-12-04       Impact factor: 9.867

10.  Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile.

Authors:  Kenneth J Oestreich; Sarah E Mohn; Amy S Weinmann
Journal:  Nat Immunol       Date:  2012-03-11       Impact factor: 25.606

View more
  43 in total

1.  ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.

Authors:  Jonathan M Weiss; Wei Chen; Melanie S Nyuydzefe; Alissa Trzeciak; Ryan Flynn; James R Tonra; Suzana Marusic; Bruce R Blazar; Samuel D Waksal; Alexandra Zanin-Zhorov
Journal:  Sci Signal       Date:  2016-07-19       Impact factor: 8.192

2.  All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.

Authors:  Hayley S Ma; Sarah M Greenblatt; Courtney M Shirley; Amy S Duffield; J Kyle Bruner; Li Li; Bao Nguyen; Eric Jung; Peter D Aplan; Gabriel Ghiaur; Richard J Jones; Donald Small
Journal:  Blood       Date:  2016-04-21       Impact factor: 22.113

Review 3.  STAT5-Driven Enhancers Tightly Control Temporal Expression of Mammary-Specific Genes.

Authors:  Ha Youn Shin; Lothar Hennighausen; Kyung Hyun Yoo
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-10-17       Impact factor: 2.673

Review 4.  Local and systemic factors and implantation: what is the evidence?

Authors:  Chelsea Fox; Scott Morin; Jae-Wook Jeong; Richard T Scott; Bruce A Lessey
Journal:  Fertil Steril       Date:  2016-03-03       Impact factor: 7.329

5.  p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Authors:  Amir Sonnenblick; Roberto Salgado; Sylvain Brohée; Tamar Zahavi; Tamar Peretz; Gert Van den Eynden; Ghizlane Rouas; Asher Salmon; Prudence A Francis; Angelo Di Leo; John P A Crown; Giuseppe Viale; Laura Daly; Bahar Javdan; Sho Fujisawa; Evandro De Azambuja; Ameye Lieveke; Martine J Piccart; Jacqueline F Bromberg; Christos Sotiriou
Journal:  Int J Oncol       Date:  2017-11-27       Impact factor: 5.650

Review 6.  The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.

Authors:  Mariano G Cardenas; Erin Oswald; Wenbo Yu; Fengtian Xue; Alexander D MacKerell; Ari M Melnick
Journal:  Clin Cancer Res       Date:  2016-11-23       Impact factor: 12.531

7.  BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.

Authors:  Jie Ding; Wilhelm G Dirks; Stefan Ehrentraut; Robert Geffers; Roderick A F MacLeod; Stefan Nagel; Claudia Pommerenke; Julia Romani; Michaela Scherr; Lea A I Vaas; Margarete Zaborski; Hans G Drexler; Hilmar Quentmeier
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

8.  STAT3 Impairs STAT5 Activation in the Development of IL-9-Secreting T Cells.

Authors:  Matthew R Olson; Felipe Fortino Verdan; Matthew M Hufford; Alexander L Dent; Mark H Kaplan
Journal:  J Immunol       Date:  2016-03-14       Impact factor: 5.422

9.  Reciprocal occupancy of BCL6 and STAT5 on Growth Hormone target genes: contrasting transcriptional outcomes and promoter-specific roles of p300 and HDAC3.

Authors:  Grace Lin; Christopher R LaPensee; Zhaohui S Qin; Jessica Schwartz
Journal:  Mol Cell Endocrinol       Date:  2014-08-01       Impact factor: 4.102

10.  Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.

Authors:  Akihiro Fujimoto; Mayuko Furuta; Yasushi Totoki; Tatsuhiko Tsunoda; Mamoru Kato; Yuichi Shiraishi; Hiroko Tanaka; Hiroaki Taniguchi; Yoshiiku Kawakami; Masaki Ueno; Kunihito Gotoh; Shun-Ichi Ariizumi; Christopher P Wardell; Shinya Hayami; Toru Nakamura; Hiroshi Aikata; Koji Arihiro; Keith A Boroevich; Tetsuo Abe; Kaoru Nakano; Kazuhiro Maejima; Aya Sasaki-Oku; Ayako Ohsawa; Tetsuo Shibuya; Hiromi Nakamura; Natsuko Hama; Fumie Hosoda; Yasuhito Arai; Shoko Ohashi; Tomoko Urushidate; Genta Nagae; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Hidenori Ojima; Nobuyoshi Hiraoka; Takuji Okusaka; Michiaki Kubo; Shigeru Marubashi; Terumasa Yamada; Satoshi Hirano; Masakazu Yamamoto; Hideki Ohdan; Kazuaki Shimada; Osamu Ishikawa; Hiroki Yamaue; Kazuki Chayama; Satoru Miyano; Hiroyuki Aburatani; Tatsuhiro Shibata; Hidewaki Nakagawa
Journal:  Nat Genet       Date:  2016-04-11       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.